In EGFR-mutated NSCLC, inhibition of the Shh pathway sensitizes primary tissues and cancer cell lines both to classic chemotherapy and EGFR-TKIs, suggesting a role for Hh pathway in resistance to EGFR TKI (22). This evidence concerns the gene EGFR and non-small cell lung carcinoma.